Capricor Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    5493002ZI5PDLXV4DX14
    ISIN
    US14070B3096 (CAPR)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €11.42M
    Gross margin
    94.5%
    EBIT
    -€62.62M
    EBIT margin
    -548.1%
    Net income
    -€59.69M
    Net margin
    -522.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A N/A
    €72.21M -€2.80M
    €133.07M +84.3% €37.73M -1,448.8%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 13, 2024

    Add to watchlist

    Notifications